
U.S. FDA declines to approve Amryt’s topical gel for rare skin diseases
The agency has asked Amryt to submit additional data confirming effectiveness of the drug.
The agency has asked Amryt to submit additional data confirming effectiveness of the drug.
Vonjo (pacritinib) belongs to a class of anti-inflammatory drugs known as JAK inhibitors, and it will compete with Incyte Corp’s Jakafi and Bristol Myers’ Inrebic, which were authorised for treating Myelofibrosis in 2011 and 2019, respectively